Advances In The Acute Management Of Cardiac Arrest

A 47-year-old man presents with nonspecific chest discomfort intermittently over the past 3 days. Episodes are not related to exertion and last 10 to 30 minutes. He has a history of hypertension and smokes 1 pack per day. In the ED, he is pain free and has an ECG with evidence of left ventricular hypertrophy and j-point elevation. You doubt that he has an acute cardiac syndrome but decide to err on the conservative side and admit him to your observation unit. The patient looks well, his first troponin is negative, and the monitor continues to show a normal sinus rhythm. Two hours later you go to check on the patient and find him disconnected from his monitor, unresponsive, and with no pulse [no wonder there was so much beeping coming from the obs unit]. The nurse has been on break for the past 30 minutes, and due to “sick calls” there was no cross coverage. You call for help which doesn’t immediately come, and you must decide what is more important — beginning chest compressions, securing the airway, getting intravenous access, or getting the defibrillator. You decide on chest compressions but are not inclined to begin mouth to mouth — you wonder if that is negligence. When the crash cart finally arrives, you note the new biphasic defibrillator and wonder what voltage to start at and if you should “stack” shocks the way you used to. The nurse asks if you want to stop CPR to establish intravenous access and what drugs you want. You begin to realize there is more that you’re unsure of than you would like to admit.

Cardiac arrest is the cessation of effective cardiac output as a result of either ventricular asystole, ventricular tachycardia, or ventricular fibrillation (VT/VF); the end result is sudden cardiac death (SCD).1 Sudden cardiac death describes the unexpected natural death from cardiac cause within 1 hour of onset of symptoms in a person without

Editor-in-Chief
Andy Jagoda, MD, FACEP
Professor and Vice-Chair of Academic Affairs, Department of Emergency Medicine, Mount Sinai School of Medicine; Medical Director, Mount Sinai Hospital, New York, NY

Editorial Board
William J. Brady, MD
Professor of Emergency Medicine and Medicine Vice Chair of Emergency Medicine, University of Virginia School of Medicine, Charlottesville, VA

Peter DeBlieux, MD
Professor of Clinical Medicine, LSU Health Science Center; Director of Emergency Medicine Services, University Hospital, New Orleans, LA

Wyatt W. Decker, MD
Chair and Associate Professor of Emergency Medicine, Mayo Clinic College of Medicine, Rochester, MN

Francis M. Fesmire, MD, FACEP
Director, Heart-Stroke Center, Erlanger Medical Center; Assistant Professor, UT College of Medicine, Chattanooga, TN

Michael A. Gibbs, MD, FACEP
Chief, Department of Emergency Medicine, Maine Medical Center, Portland, ME

Steven A. Godwin, MD, FACEP
Assistant Professor and Emergency Medicine Residency Director, University of Florida HSC, Jacksonville, FL

Gregory L. Henry, MD, FACEP
CEO, Medical Practice Risk Assessment, Inc.; Clinical Professor of Emergency Medicine, University of Michigan, Ann Arbor, MI

John M. Howell, MD, FACEP
Clinical Professor of Emergency Medicine, George Washington University, Washington, DC; Director of Academic Affairs, Best Practices, Inc, Inova Fairfax Hospital, Falls Church, VA

Keith A. Marvil, MD
Assistant Professor, Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Francesca S. Merusi, MD, FACEP
Director, Heart-Stroke Center, Erlanger Medical Center; Assistant Professor, UT College of Medicine, Chattanooga, TN

Charles V. Pollack, Jr., MA, MD, FACEP
Chairman, Department of Emergency Medicine, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA

Michael S. Radeos, MD, MPH
Research Director, Department of Emergency Medicine, New York Hospital Queens, Flushing, NY; Assistant Professor of Emergency Medicine, Weill Medical College of Cornell University, New York, NY

Robert L. Rogers, MD, FAAEM
Assistant Professor and Residency Director, Combined EM/IM Program, University of Maryland, Baltimore, MD

Alfred Sacchetti, MD, FACEP
Assistant Clinical Professor, Department of Emergency Medicine, Thomas Jefferson, Philadelphia, PA

Scott Silvers, MD, FACEP
Assistant Professor; Division Chief, Department of Community and Preventive Medicine, Mount Sinai Medical Center, New York, NY

Valerio Gai, MD
Senior Editor, Professor and Chair, Department of Emergency Medicine, University of Turin, Turin, Italy

Peter Cameron, MD
Chair, Emergency Medicine, Monash University; Alfred Hospital, Melbourne, Australia

Amin Antoine Kazzi, MD, FAAEM
Associate Professor and Vice Chair, Department of Emergency Medicine, University of California, Irvine; American University, Beirut, Lebanon

Hugo Peralta, MD
Chair of Emergency Services, Hospital Italiano, Buenos Aires, Argentina

Maarten Simons, MD, PhD
Emergency Medicine Residency Director, OLVG Hospital, Amsterdam, The Netherlands

September 2008
Volume 10, Number 9

Authors
Bakhtiar Ali, MD
Atlanta Veterans Affairs Medical Center, Decatur, GA

A. Maziar Zafari, MD, PhD, FACC, FAHA
Atlanta Veterans Affairs Medical Center, Decatur, Georgia; Emory University School of Medicine, Division of Cardiology, Atlanta, GA

Peer Reviewers
Bentley J. Bobrow, MD, FACEP
Assistant Professor of Emergency Medicine, Department of Emergency Medicine, College of Medicine, Mayo Clinic, Scottsdale, AZ; Medical Director Bureau of Emergency Medical Services and Trauma System, Arizona Department of Health Services, Phoenix, AZ

Barbara K. Richardson, MD, FACEP
Associate Professor, Emergency Medicine, Mount Sinai School of Medicine, New York, NY

CME Objectives
Upon completion of this article, you should be able to:
1. Identify the significant changes in the 2005 American Heart Association guidelines.
2. Examine the evidence which prompted changes to the American Heart Association guidelines.
3. Indicate future therapies that may impact outcomes from sudden cardiac death.

Date of original release: September 1, 2008
Date of most recent peer review: August 10, 2008
Termination date: September 1, 2011

Method of participation: Print or online answer form and evaluation
Prior to beginning this activity, see “Physician CME Information” on the back page.

International Editors

Valerio Gai, MD
Senior Editor, Professor and Chair, Department of Emergency Medicine, University of Turin, Turin, Italy

Peter Cameron, MD
Chair, Emergency Medicine, Monash University; Alfred Hospital, Melbourne, Australia

Amin Antoine Kazzi, MD, FAAEM
Associate Professor and Vice Chair, Department of Emergency Medicine, University of California, Irvine; American University, Beirut, Lebanon

Hugo Peralta, MD
Chair of Emergency Services, Hospital Italiano, Buenos Aires, Argentina

Maarten Simons, MD, PhD
Emergency Medicine Residency Director, OLVG Hospital, Amsterdam, The Netherlands

Commercial Support: Emergency Medicine Practice does not accept any commercial support.
any prior condition that appears fatal.2  
In 2005, the American Heart Association (AHA) released updated guidelines based on the International Consensus Conference on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment recommendations.3 These recommendations are based on both experimental data and expert consensus. The new guidelines incorporated significant changes in the algorithms in the treatment of cardiac arrest (Table 1). The AHA also identified future areas of research that may impact outcomes in cases of cardiac arrest. These changes include the manner in which CPR is to be carried out with increased emphasis on the continuity of chest compressions with minimal interruptions. This issue of Emergency Medicine Practice highlights significant changes in the 2005 AHA guidelines, examines the evidence that prompted the changes, and explores future therapies that may impact outcomes from SCD.

Critical Appraisal Of The Literature

A literature search for articles between 1966 and 2008 was performed using PubMed. Search terms included sudden cardiac death, cardiac arrest, and VT/VF. Both animal and human studies were included. The broad search yielded approximately 4000 articles in addition to the 2005 AHA guidelines for CPR and emergency cardiovascular care. Abstracts were reviewed, and 120 articles were identified, 89 of which are cited.

The closed chest method of CPR was first described by Kouwenhoven et al in a landmark article in 1960.3 Due to the nature of the problem of SCD, prospective randomized trials are difficult to conduct. Even after 48 years, a significant portion of management of SCD is based on animal experiments and expert consensus. However, over the past 15 years an increasing number of evidence-based management strategies were put into practice, as reflected by the most updated AHA guidelines. The classification of AHA recommendations is presented in Table 2. In this review, we use the classification system consistent with the AHA and the American College of Cardiology collaboration on evidence-based guidelines.6 Class I recommendations were based on high-level prospective studies where the benefit substantially outweighs the potential of harm. Class IIa recommendations were based on cumulative weight of evidence, and the therapy is considered acceptable and useful.8 When a therapy demonstrates only short-term benefit or when a positive result was based on lower level of evidence, a Class IIb recommendation was used. For Class III therapies, there is evidence and/or general agreement that the procedure/treatment is not useful/effective and in some cases may be harmful. Class Indeterminate are therapies for which further research is required.9 Generally, Class I and Class IIa recommendations support standard of care. Deviation from the recommendation should be addressed in a clinical decision making note on the chart.

| Table 1. Important Changes In The 2005 AHA Guidelines For CPR And Emergency Cardiovascular Care |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Measure                                   | 2000 Recommendation                        | 2005 Recommendation                        |
| Immediate defibrillation for unwitnessed cardiac arrest | Recommended | 5 cycles of CPR prior to shock is recommended |
| Compression: ventilation ratio            | 15:2                                        | 30:2                                        |
| Sequence of defibrillation                | 3 stacked shocks                            | 1 shock only followed by immediate CPR      |
| Rhythm/pulse check                        | After each shock                            | After 5 cycles of CPR following each shock  |


<table>
<thead>
<tr>
<th>Table 2. The AHA Classification Of Recommendations And Level Of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
</tr>
<tr>
<td>Class II</td>
</tr>
<tr>
<td>IIa. Weight of evidence/opinion is in favor of usefulness/efficacy</td>
</tr>
<tr>
<td>IIb. Usefulness/efficacy is less well established by evidence/opinion</td>
</tr>
<tr>
<td>Class III</td>
</tr>
<tr>
<td>Class Indeterminate</td>
</tr>
</tbody>
</table>

Epidemiology, Etiology, Pathophysiology

Sudden cardiac death accounts for 300,000 to 400,000 deaths every year in the United States.2 The incidence of SCD is 54 to 55 per 100,000 persons.7 Rea et al calculated that SCD accounts for 5.6% of the annual mortality in the United States.8 Zheng and colleagues reported 63% of all cardiac deaths as...
The proportion of cardiovascular death from SCD has remained constant over the past several years despite the fact that mortality from cardiovascular cause has decreased. This may be due to the infrequency of bystander CPR and the fact that approximately 80% of SCDs occur at home.

The most common etiology for SCD is CAD followed by cardiomyopathies (Figure 1). Together, these cardiovascular diseases account for 95% of SCDs (Table 3). It is important to account for uncommon causes of SCD as they may have treatment implications. These diseases include aortic stenosis, congenital heart disease, Wolff-Parkinson-White (WPW) syndrome, prolonged QT, and Brugada syndrome, a common etiology of SCD in Asian men less than 50 years of age. Acute insults including hypoxia, ischemia, acidosis, electrolyte imbalances, and toxic effects of certain drugs may act on the structural substrate and produce arrhythmias leading to SCD and cardiac arrest.

The presenting rhythm in cardiac arrest is variable, with new studies suggesting a decreasing incidence of VT/VF (21%-32%) for cardiac arrest and a higher incidence of asystole and pulseless electrical activity (PEA). In a multicenter, randomized trial (N= 757) studying out-of-hospital cardiac arrest, 31% of subjects presented with an initial rhythm of VT/VF. In another study with a cohort of 783 out-of-hospital cardiac arrest subjects, 22% presented with an initial rhythm of VT/VF. The National Registry of Cardiopulmonary Resuscitation (NRCPR) reported 25% of initial rhythm in 14,720 victims of in-hospital cardiac arrest as VT/VF. A heart in VT/VF is thought to deteriorate to PEA and asystole with time, conditions which are less responsive to treatment.

The temporal sequence of cardiac arrest can be understood by a 3-phased time sensitive model as proposed by Weisfeldt and Becker (Figure 2). These phases include electrical (lasting 0 to 4 minutes from time of cardiac arrest), circulatory (lasting approximately 4 to 10 minutes from time of cardiac arrest), and metabolic (lasting > 10 minutes from time of cardiac arrest), and they require specific treatments. During the electrical phase, defibrillation is the most effective treatment for cardiac arrest. In the circulatory phase, good quality CPR gains increasing importance along with defibrillation. In the third and final metabolic phase, there is global ischemic injury, where therapeutic strategies that focus on metabolic derangements are critical.

Therapeutic hypothermia for comatose survivors of SCD may assist in neurologic recovery at this stage.

Patients with cardiac arrest present both in-hospital and out-of-hospital. The majority of SCDs occur at home and are witnessed by relatives of cardiac arrest victims. In a prospective study of out-of-hospital SCDs conducted in Europe, bystander interviews were conducted by emergency physicians on site after return of spontaneous circulation (ROSC) or death. The study identified 406 cardiac arrest patients out of 5831 rescue missions. In 72% of the cardiac arrest patients, events occurred at home. Of the witnessed cardiac arrest victims, only 14% received bystander resuscitation even though 66% of witnesses were relatives of the victim. Most notably, 55% of SCD victims reported cardiac symptoms 1 hour prior to collapse. These symptoms included chest pain, syncope, and dyspnea.

---

**Figure 1.** A Confluence Of Risk Factors Act Together To Produce Sudden Cardiac Death

<table>
<thead>
<tr>
<th>Transient risk factors</th>
<th>SCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemia</td>
<td></td>
</tr>
<tr>
<td>Hypoxia</td>
<td></td>
</tr>
<tr>
<td>Hypotension</td>
<td></td>
</tr>
<tr>
<td>Acidosis</td>
<td></td>
</tr>
<tr>
<td>Electrolyte imbalances</td>
<td></td>
</tr>
<tr>
<td>Drug effects</td>
<td></td>
</tr>
</tbody>
</table>

Long-term medical problems (coronary artery disease and cardiomyopathies) produce structural pathology in the myocardium on which transient factors act and trigger ventricular tachycardia and ventricular fibrillation. People with risk factors for coronary artery disease are at high risk for sudden cardiac death.

**Figure 2.** Graphic Representation Of The 3-Phase Time Sensitive Model Of Cardiac Arrest

This model predicts 50% survival rate for defibrillation provided in the electrical phase where electrical phase = 0 to 4 minutes, circulatory phase = 4 to 10 minutes, and metabolic phase > 10 minutes (based on the model described by Weisfeldt and Becker. JAMA. 2002).
majority of SCD victims have a known history of either cardiovascular disease (CVD) or cardiac symptoms.\textsuperscript{18} However, almost half of the patients will present without any symptoms and will present as unresponsive with no spontaneous respirations or pulse.\textsuperscript{18}

### Differential Diagnosis

Sudden cardiac death occurs in the setting of an acute insult acting most commonly on a pathological structural substrate (Table 4). They include acidosis, acute myocardial infarction, cardiac tamponade, hypoxia, hypovolemia, hyperkalemia, hypokalemia, hypoglycemia, hypothermia, pulmonary embolism, effect of certain toxins or drugs, and tension pneumothorax.\textsuperscript{11,12} During CPR, it is critical for the clinician to seek clues from the medical history and family and to treat for the contributing factors, some of which may be rapidly reversible. Point of care testing can guide the need for treatment of hyperglycemia, hypoglycemia, acidosis, hyperkalemia, or hypokalemia. Bedside sonography when immediately available is increasingly used by trained emergency physicians to check for cardiac activity in PEA/asystole, pericardial effusion, or suspected aortic catastrophe.

Hypoxia, hypovolemia, and hypoglycemia can be rapidly assessed and treated through adequate ventilation, fluid resuscitation, and a finger stick test and dextrose water. If acidosis is suspected, it can be reversed by infusion of sodium bicarbonate solution. Hyperkalemia can cause bradyarrhythmic arrest. It may or may not produce the typical ECG features of prolonged PR intervals and peaked T waves (Figure 3). It should be treated with 10 units of regular insulin with glucose in normoglycemic patients. If hyperkalemia is detected prior to cardiac arrest, calcium gluconate, 10 mL in 10% solution over 10 to 20 minutes, should be given to stabilize electrical effects on cardiac myocytes.\textsuperscript{19} If hyperkalemia is suspected during cardiac arrest, a much faster rate should be used.

Digitalis toxicity may lead to sustained VT which is characterized by right bundle branch block configuration and alternating left and right axis deviation (Figure 4). It can be treated with infusion of digoxin Fab fragments.\textsuperscript{19} Certain drugs can prolong the QT interval in genetically predisposed individuals. These medications include: \textsuperscript{19}
- tricyclic antidepressants
- neuroleptics
- macrolide and quinolone antibiotics
- antifungal agents
- procainamide, quinidine, disopyramide (class IA antiarrhythmics)
- sotalol, dofetilide, and ibutilide (class III antiarrhythmics)

In cardiac tamponade, the patient may have symptoms and signs prior to cardiac arrest (e.g. pulses paradoxus, elevated jugular venous pulsation, distant heart sounds, and electrical alternans on ECG). Chest x-ray may show an enlarged heart. If cardiac tamponade is suspected, emergent pericardiocentesis should be performed.\textsuperscript{19}

Tension pneumothorax may occur in a patient with a history of emphysema and chest wall trauma. Decreased breath sounds on one side of the chest wall suggests pneumothorax, and in the event of cardiac arrest, it requires immediate decompression.\textsuperscript{19}

Symptoms consistent with acute myocardial infarction (e.g. angina, dyspnea, diaphoresis) may precede prior to collapse. If acute coronary syndromes and pulmonary embolism are suspected, they should be ruled out after resuscitation.\textsuperscript{18} Following ROSC in cardiac arrest, a 12-lead ECG may show ST-segment elevation myocardial infarction (STEMI). It is recommended that survivors of cardiac arrest be considered for emergent percutaneous coronary intervention if another etiology is not obvious.\textsuperscript{20}

### Initial Management

Cardiac arrest is an emergency situation in which death can occur within minutes. Factors associated with improved outcomes in cardiac arrest are listed in

### Table 3. Etiologies of Sudden Cardiac Death

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Coronary Artery Disease</strong></td>
<td></td>
</tr>
<tr>
<td>Acute Coronary Syndrome</td>
<td>Approximately 80%</td>
</tr>
<tr>
<td>Chronic Myocardial Scar</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiomyopathies</strong></td>
<td></td>
</tr>
<tr>
<td>Dilated Cardiomyopathies</td>
<td>Approximately 10%</td>
</tr>
<tr>
<td>Hypertrophic Cardiomyopathies</td>
<td>15%</td>
</tr>
<tr>
<td><strong>Uncommon Causes</strong></td>
<td></td>
</tr>
<tr>
<td>Valvular/Congenital Heart Disease</td>
<td>&lt; 5%</td>
</tr>
<tr>
<td>Myocarditis, Genetic Ion-Channel</td>
<td></td>
</tr>
<tr>
<td>Abnormalities, etc.</td>
<td></td>
</tr>
</tbody>
</table>


### Table 4. Contributing Causes Of Cardiac Arrest

<table>
<thead>
<tr>
<th>The 6 Hs</th>
<th>The 5 Ts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypovolemia</td>
<td>Toxins</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>Tamponade, cardiac</td>
</tr>
<tr>
<td>Hydrogen ion (acidosis)</td>
<td>Tension, pneumothorax</td>
</tr>
<tr>
<td>Hypokalemia/Hyperkalemia</td>
<td>Thrombosis (coronary or pulmonary)</td>
</tr>
<tr>
<td>Hypothermia</td>
<td>Trauma</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td></td>
</tr>
</tbody>
</table>

Table 5. The first priority is to check the ABCs following basic cardiovascular life support (BLS) and advanced cardiovascular life support (ACLS) protocols (see Clinical Pathway on page 10). During the resuscitative effort and after the patient is stabilized, the underlying etiologies should be continuously explored.

**Basic Cardiovascular Life Support**

The first step when encountering a victim of cardiac arrest is activation of the emergency response system and immediate initiation of CPR. If the airway is clear, 2 rescue breaths are delivered, and the carotid pulse is checked for no more than 10 seconds (Class IIa). If the patient does not have a pulse, cycles of compressions and ventilations should be started at the ratio of 30:2 (Class IIa). Chest compressions should allow for complete recoil of the chest and should be at the rate of 100 per minute (Class IIa). Each breath should be given for 1 second and should produce visible chest rise (Class IIa). The chest is compressed at the center of the nipple line at the approximate depth of 1.5 to 2 inches.

Effective chest compressions are necessary to maintain adequate coronary perfusion (Class I). Team leader monitoring of ventilation rate in resuscitation is essential, as it is invariably too fast — even among trained providers. The team leader must also monitor adequacy of compressions. The most effective method to coordinate chest compressions and ventilations and the best compression and ventilation ratio is yet to be determined.

The compression ventilation ratio has been changed from 15:2 to 30:2 to minimize interruptions to chest compressions and to prevent hyperventilation. Animal models have demonstrated that interruptions to chest compressions lead to decreased myocardial blood flow and 24-hour survival. In a clinical observational study, Aufderheide et al demonstrated an average ventilation rate of 30 ± 3.2 per minute by professional rescuers during CPR in 13 consecutive adults. In the second part of the study, ventilation rates of 30 per minute led to high intrathoracic pressures and low coronary perfusion pressures in animal models. Similarly, animal models have demonstrated that PaO$_2$ levels are maintained in the first 14 minutes of cardiac arrest when proper CPR is provided. In contrast, an experimental animal model and a prospective observational study provided support that interruptions to chest compressions decrease the probability of return to spontaneous circulation and low coronary perfusion pressures. When trained health care professionals and BLS-trained subjects were studied, it was shown that rescue breaths interrupted chest compressions for 14 to 16 seconds.

The efficacy of ventilation in CPR for cardiac arrest victims is not well established. Recently there has been increasing interest in “cardiocerebral resuscitation” which is defined as “chest compression only resuscitation.” In a retrospective study of 135 patients, Kellum et al showed improved survival (20% vs. 57%) and neurological outcomes (15% vs. 48%; P = 0.001) with application of a protocol of cardiocerebral resuscitation in victims of out-of-hospital cardiac arrest with initially shockable rhythms.

At the very least, a body of evidence supports the critical importance of minimal interruptions during CPR chest compressions. One of the most important factors impacting survival in cardiac arrest is early provision of good quality CPR and early defibrillation when indicated. Stiell et al reported the threefold higher survival rate of 2.98 (95% CI, 2.07-4.29) when CPR was provided by a bystander in an out-of-hospital cardiac arrest. In a study based on cardiac arrest victims in Las Vegas casinos, 74% of victims survived to discharge when defibrillation was delivered within 3 minutes as opposed to 49% survival rate when defibrillation was delivered after 3 minutes of downtime (P = 0.02). The results from the Swedish cardiac arrest registry demonstrated a 17.4% survival rate at 1 month for patients if CPR was provided within 2 minutes of cardiac arrest vs.

**Figure 3. Hyperkalemia**

Example of a patient with hyperkalemia. Note the peaked T waves with a narrow base and the slightly widened QRS complexes. (Reproduced with permission.)

**Figure 4. Bidirectional Ventricular Tachycardia Caused By Digitalis Toxicity**

Note the right bundle branch block pattern and alternating QRS axis. (Adapted from Kummer JL, Nair R, Krishnan SC. Circulation. 2006;113:e156-157)
6.9% if provided after 2 minutes (P = 0.001). The authors also reported an odds ratio of 3.5 (95% CI, 2.9-4.3) for survival with bystander CPR. In the setting of in-hospital cardiac arrest, 38% of patients survived to discharge when defibrillation was provided within 3 minutes vs. 21% when shock was provided after 3 minutes (P = 0.001).

In a 2008 study, Chan et al studied in-hospital cardiac arrest and the impact of delay in defibrillation on outcome. Delay was defined as more than 2 minutes from loss of pulse to defibrillation. The study identified 6789 patients with VT/VF cardiac arrest from 369 hospitals. In 2045 patients (30.1%), defibrillation occurred after 2 minutes. The authors reported that delay resulted in a lower probability of survival to hospital discharge when compared to defibrillation without delay (22% vs. 39.3%, P = 0.001). In a prospective study involving 193 patients, White et al reported a mean time to shock interval of 5.6 ± 1.5 minutes for survival to discharge for out-of-hospital cardiac arrest and 6.7 ± 1.8 minutes for non-survivors (P <0.001).

The second important change in the BLS guidelines distinguishes between witnessed and un-witnessed cardiac arrest. If the cardiac arrest is witnessed and of short duration with an initial rhythm of VT/VF, the patient should be immediately defibrillated (Class I). However, if the downtime is unknown, 2 minutes of CPR is recommended prior to defibrillation for a shockable rhythm (Class IIb). These changes were prompted by results of 2 important studies. The first study was a prospective observational study in the out-of-hospital VT/VF cardiac arrest setting; when the response time was greater than 4 minutes, the victims benefited from 90 seconds of CPR prior to defibrillation. The “CPR first” group had a 27% survival rate vs. 17% when shock was delivered prior to CPR (P = 0.01). The “CPR first” group also showed improved neurological outcomes regardless of response time. These findings were confirmed by Wik and colleagues in a randomized trial. They studied out-of-hospital VT/VF cardiac arrest victims, with the first group receiving 3 minutes of CPR prior to defibrillation and the second group receiving immediate defibrillation. In patients with a response time of ≥ 5 minutes, the “CPR first” group had a 22% survival to discharge vs. a 4% survival to discharge for the “defibrillation first” group (P = 0.006). This survival difference was also confirmed at 1 year (20% vs. 4%, P = 0.01).

Conversely, no difference in survival was observed in a prospective randomized trial involving 256 patients of out-of-hospital VT/VF cardiac arrest in which one group received 90 seconds of CPR prior to shock and the other group received immediate defibrillation. Therefore, the current guidelines use permissive language while recommending CPR first in an unobserved cardiac arrest.

The most recent guidelines recommend a single shock protocol in BLS instead of the previously recommended protocol using 3 stacked shocks. There is no evidence that the protocol utilizing 1 shock is better than 3 stacked shocks in the management of VT/VF cardiac arrest. However, there is evidence that the 1-shock protocol may lead to better quality of CPR. Studies have demonstrated that the protocol using 3 stacked shocks results in unacceptably prolonged interruptions in the delivery of CPR. Probability of ROSC decreases if there is an interruption of CPR for > 20 seconds. In a study by Van Alem et al, the mean delay for the resumption of CPR was 40 seconds after the first shock, and in none of the 123 patients was CPR resumed within 20 seconds. Another study described a “hands off” interval of 19 to 25 seconds between shocks with no CPR. Berg and colleagues described a mean delay of 38 seconds for resumption of post-shock CPR. The interruption of chest compressions during CPR leads to poor outcomes. In addition, interrupted chest compressions during CPR for rhythm analysis correlated with low arterial pressures, low coronary perfusion, and decreased ejection fraction. Analysis of heart rhythms have shown that the initial rhythm after defibrillation is either asystole or some other non-perfusing rhythm approximately 60% of the time. Therefore, immediate CPR after delivery of the first shock is advocated in the current recommendations (Class IIa). The first shock should be followed by 2 minutes of CPR which comprises of 5 cycles of CPR at a ratio of 30:2 chest compressions to ventilations. Only then should the rhythm be analyzed. If an organized rhythm is seen, then the pulse is checked; otherwise, CPR is continued.

### Table 5. Factors Associated With Improved Outcomes in Cardiac Arrest

- Presenting rhythm of VT/VF
- Early/bystander CPR
- Early defibrillation
- CPR prior to defibrillation in the circulatory phase of cardiac arrest
- Minimal interruptions to chest compressions
- In-hospital and out-of-hospital use of AEDs
- Amiodarone use in shock-resistant VT/VF
- Therapeutic hypothermia in comatose cardiac arrest victims

### Monophasic And Biphasic Waveforms

Currently, defibrillation devices use 2 kinds of waveforms: monophasic and biphasic (Table 6). A successful defibrillation is defined as absence of VT/VF at 5 seconds after shock delivery. Even though there is a lack of clear-cut evidence for the superiority of biphasic devices in terms of survival, use of biphasic devices is increasing in prevalence. Direction of current is unidirectional in monophasic waveforms and bidirectional in biphasic waveforms, with typical energy levels of 200 to 360 J for monophasic devices and 120-200 J for biphasic devices. Weaver et al demonstrated a higher incidence of atrioventricular block when
repeated shocks of high energy monophasic waveforms were delivered. In a prospective randomized trial comparing efficacy of monophasic and biphasic waveforms, first shock success rates were 96% for biphasic devices compared to 54% to 77% for monophasic devices. Similarly, another study demonstrated a higher first shock success rate with biphasic devices compared to monophasic devices (98% vs. 69%; P = 0.0001), and the authors described better neurological status for patients defibrillated with biphasic devices (87% vs. 53%). The authors failed to demonstrate the mechanism of improved cerebral outcomes, and a recent study comparing monophasic and biphasic devices demonstrated neither higher first shock success rates nor improved cerebral outcomes for biphasic devices. None of the studies comparing the 2 waveforms demonstrated any advantage in terms of ROSC or survival rates for any one waveform. There is no strong evidence backing the increased use of biphasic devices. Replacement of obsolete defibrillators is favoring the biphasic defibrillators, the theory being that lower joules with equivalent efficacy save more myocardium.

In the interest of applicability, the AHA guidelines recommend a dose of 360 J in a non-escalating manner when a monophasic device is used. The appropriate energy level for biphasic waveforms is device-specific, typically 120 J with a rectilinear waveform and 150 to 200 J for a truncated exponential waveform. Subsequent shocks may be given at the same or higher energy level (Class IIa). CPR should be continued until the defibrillator is charged and the patient is cleared for shock delivery.

Automated External Defibrillators
AEDs are simple, safe, and effective devices designed to be used by both medical professionals and lay people during CPR. There is evidence that use of AEDs leads to early defibrillation and better survival in both in-hospital and out-of-hospital cardiac arrest. When the use of “CPR+AED” in public areas by the general public was compared to CPR by general public and AED use by emergency medical services only, the “CPR+AED” group not only had shorter time for initial rhythm assessment (6.0 ± 4.7 minutes vs. 8.7 ± 5.5 minutes; P = 0.001) but also doubled the number of patients (30 vs. 15; P = 0.03) surviving to hospital discharge. In the case of in-hospital cardiac arrest, a single site study encouraging early defibrillation with use of AEDs demonstrated a 2.6-fold increase in survival to discharge from 4.9% to 12.8%; P = 0.001.

Advanced Cardiovascular Life Support
BLS measures have more impact on survival in cardiac arrest when compared to measures of advanced cardiovascular support. The Ontario Prehospital Advanced Life Support (OPALS) study was designed as a multicenter, prospective, observational study and compared outcomes for 4247 patients of out-of-hospital cardiac arrest who received prehospital ACLS vs. a historical cohort of 1391 patients who received only prehospital BLS and defibrillation. The study showed that even though institution of ACLS increased the number of people admitted alive to the hospital (10.9% vs. 14.6%; P <0.001), no advantage was present if survival to hospital discharge was taken into account (5.0% vs. 5.1%; P = 0.83). High quality CPR and rapid defibrillation are the most important measures in the management of cardiac arrest.

Administration Of Medications During CPR
Traditionally, medications have been administered via intravenous or endotracheal route during CPR. It is a common practice in hospitals to attempt placing a central venous access line emergently. However, there is limited evidence of superiority of central venous access over peripheral venous access during CPR. In addition, there is potential of interruption of CPR during attempted placement of a central access line which is clearly detrimental for the patient. Use of central venous access leads to higher peak drug levels and earlier attainment of effective drug levels compared to peripheral access, but this advantage may not be present for femoral access lines.

If intravenous access cannot be established, drugs may be administered through an intraosseous route or through the endotracheal tube. New devices for rapid intraosseous access in adults using a drill can be placed promptly. This has often been an access route in pediatric CPR but appears to be gaining favor in adults as well when traditional access cannot be achieved. Epinephrine and atropine are among the drugs that can be given via the endotracheal route. The endotracheal route requires higher concentrations of epinephrine than the intravenous route. In a retrospective study comparing the outcomes of endotracheal vs. intravenous drug administration in out-of-hospital cardiac arrest patients, Niemann et al found that none of the patients who received drugs via the endotracheal tube survived to discharge. Endotracheal drugs should only be administered if no intravenous access is available.

| Table 6. Comparison Of Monophasic And Biphasic Waveforms |
|---------------------------------|-----------------|
| **Monophasic** | **Biphasic** |
| Current direction | Unidirectional | Bidirectional |
| Typical energy level | 200 J to 300 J | 120 J to 200 J |
| First shock success rates* | 90% to 95% | 60% to 90% |
| Higher rates of ROSC | Not demonstrated | Not demonstrated |
| Survival benefit | Not demonstrated | Not demonstrated |
| AV nodal block | Demonstrated with repeated high energy shocks | Not demonstrated |

Peripheral access is preferable over central, and intravenous access is preferable over endotracheal for drug administration during CPR.

Role Of Medications During CPR

**Epinephrine:** Use of epinephrine in cardiopulmonary resuscitation dates back to more than a century. Epinephrine is an α- and β-receptor agonist. The main benefit during CPR is derived from increased peripheral vascular resistance via the stimulation of α-receptors of the blood vessels. This results in the effective redistribution of blood flow from visceral organs to the heart and brain. There is a possible detrimental effect of β-receptor stimulation by causing increased metabolic demand in the heart.

The appropriate dosing regimen of epinephrine has been subject to some controversy, with experimental data in animal models showing benefit for higher doses. In a double-blind, prospective study in France involving 536 patients with out-of-hospital cardiac arrest, with one group receiving standard 1 mg of epinephrine and the second group receiving 5 mg of epinephrine, no statistically significant differences were observed in the ROSC as well as in short-term and long-term survival rates. This study was followed by a larger, multi-center, prospective, and double-blind study involving 3327 patients suffering out-of-hospital cardiac arrest. Patients were randomized to a standard group receiving 1 mg of epinephrine and a high-dose group receiving 5 mg of epinephrine for up to a total of 15 doses given at 3-minute intervals along with standard CPR. Even though the high-dose group achieved a higher rate of ROSC and higher hospital admission rate, only a small number of patients survived to hospital discharge. In fact, the high-dose group had a higher in-hospital mortality rate during the first 24 hours. There was no statistically significant difference in the rates of discharge from hospital or cerebral performance at discharge in survivors between the groups.

Currently, 1 mg of epinephrine intravenously is recommended in a concentration of 1:10,000 every 3 to 5 minutes in order to resuscitate victims of all forms of cardiac arrest (Class IIb).

**Vasopressin:** Another area of controversy is the role of vasopressin in CPR. Vasopressin causes peripheral vasoconstriction by acting on vasopressin receptors and bypassing the adrenergic system. It has a longer half-life than epinephrine, approximately 20 minutes, and has the ability to act in an acidic environment in contrast to epinephrine.

Use of vasopressin was initially established by a small study involving 40 patients in which 40 IU of vasopressin showed better ROSC and better survival in the first 24 hours in out-of-hospital cardiac arrest caused by VT/VF; thus, vasopressin 40 IU was recommended in the management of refractory VT/VF in the 2000 AHA guidelines. This small study was followed by 2 larger prospective studies. The first study (N = 200) compared 40 IU of vasopressin with 1 mg of epinephrine in cardiac arrest victims regardless of presenting rhythm. This study did not find any difference in ROSC, survival, and neurological outcomes between the 2 groups. The second study involved 1219 patients and compared 1 mg of epinephrine to 40 IU of vasopressin in out-of-hospital cardiac arrest patients. This study did not show significant differences in hospital admission and survival rates between the groups. Nonetheless, if presenting rhythms were considered, asystolic patients in the vasopressin group showed a higher rate of hospital admission (29% vs. 20.3%; P = 0.02) and survival to discharge (4.7% vs. 1.5%; P = 0.04) compared to the epinephrine group. Patients in asystole who received additional epinephrine along with vasopressin showed a higher rate of hospital admission (22.5% vs. 13.3%; P = 0.02) and survival to discharge (3.8% vs. 0; P = 0.008) when compared to patients who received repeated doses of epinephrine alone. However, there was a disturbingly high incidence of cerebral dysfunction in patients who were discharged after asystole. A retrospective analysis of 298 out-of-hospital cardiac arrests patients showed better pulse return with the combination of epinephrine and vasopressin (40% vs. 13%; P = 0.008) and better ROSC (33% vs. 8.7%; P = 0.004) when the presenting rhythm was asystole.

However, the authors did not describe any improved outcomes in terms of survival. Therefore, even though use of vasopressin is allowed by the current AHA guidelines, there is limited evidence of superiority of vasopressin over epinephrine in any form of cardiac arrest. There is no compelling reason to prefer vasopressin over epinephrine, and further trials need to be conducted to further define the role of vasopressin, particularly in asystolic cardiac arrest.

Currently, vasopressin 40 IU intravenously is recommended as an alternative to epinephrine for refractory VT/VF as well as PEA/asystole when intravenous or intraosseous access is established (Class Indeterminate).

**Atropine:** Experimental evidence for the efficacy of atropine in cardiac arrest is limited. One mg of atropine intravenously, every 3 to 5 minutes (maximum dose 3 mg), is recommended for use in asystole and slow PEA along with epinephrine and vasopressin (Class Indeterminate). Atropine is an acetylcholine receptor antagonist of the muscarinic type. Parasympathetic stimulation of the heart results in negative inotropic and chronotropic effects, and atropine is used to block the parasympathetic effect on the heart. A small prospective study involving 21 patients did not show any advantage of atropine in patients with out-of-hospital cardiac arrest. In contrast, a retrospective study of refractory asystole showed an advantage of atropine in out-of-hospital cardiac arrest.
In the latter study, the atropine group had a higher number of patients admitted alive to the emergency department but none survived to hospital discharge.70

**Amiodarone:** Amiodarone is the first-line antiarrhythmic for shock refractory VT. In contrast to lidocaine, efficacy of amiodarone to convert VT/VF rhythms to perfusing rhythms in cardiac arrest has been established by 2 prospective randomized trials. The first trial was a randomized, double blind, placebo-controlled study involving 504 eligible patients. This study compared 300 mg of amiodarone to placebo in patients with out-of-hospital cardiac arrest due to ventricular fibrillation. Amiodarone was administered when CPR, 3 shocks, and epinephrine failed to convert the rhythm. Amiodarone showed a higher rate of successful resuscitation and admission to hospital than placebo, odds ratio 1.6 (95% CI, 1.1-2.4; P = 0.02).71 The study was underpowered to detect differences in survival to hospital discharge. The Amiodarone vs. Lidocaine in Prehospital Ventricular Fibrillation Evaluation (ALIVE) trial compared amiodarone 5 mg/kg to lidocaine 1.5 mg/kg for shock-resistant ventricular fibrillation.72 This study enrolled 347 patients and demonstrated superiority of amiodarone over lidocaine in terms of survival to hospital admission (22.8 % vs. 12. %; P = 0.009); this superiority was present regardless of presenting rhythm and was demonstrated over an extended period of time. The lidocaine group had a higher incidence of asystole after defibrillation, following the study-drug delivery.72 Neither of the 2 trials showed long-term survival benefit for amiodarone.

Polysorbate 80 and benzoyl alcohol are used as diluents for amiodarone, which may cause hypotension during the resuscitative efforts.73 However, the incidence of hypotension was not statistically significant when compared to lidocaine in the ALIVE trial. In addition, studies by the amino-aqueous investigators on the aqueous formulation of amiodarone did not show any increase in incidence of hypotension. The added advantage of aqueous formulation of amiodarone is that it can be infused rapidly compared to the standard formulation.73, 74

Amiodarone 300 mg is used intravenously when CPR, 3 shocks, and vasopressors have failed to convert the rhythm in cardiac arrest (**Class IIb**). The **Class IIb** recommendation is indicative of the short-term benefit of amiodarone.6 The initial dose can be followed by a second dose of 150 mg.

**Lidocaine:** Use of lidocaine in shock refractory VF/VT is not established by any clinical evidence. It should not be used as a first-line antiarrhythmic agent during the management of cardiac arrest (**Class Indeterminate**). Lidocaine may increase the incidence of asystole in cardiac arrest due to ventricular arrhythmias.72, 73

**Magnesium Sulfate:** One to 2 g of magnesium sulfate diluted in 10 mL of dextrose water is used to treat VT/VF presenting as **torsades de pointes** during CPR (**Class IIa**). **Torsades de pointes** is a polymorphic VT associated with a prolonged QT interval. The evidence to support this indication is very limited, and there are no randomized trials to support it. Despite the paucity of evidence, the AHA has chosen to make it a **Class IIa** recommendation.80 In a small study, Tzivoni et al terminated VT in 11 out of 12 patients by using boluses of 2 g magnesium sulfate followed by continuous infusion of 3 to 20 g/minute.76

**Post-Resuscitative Care**

In patients with return of spontaneous circulation (ROSC) with CPR, the objectives of post-resuscitative care include optimization of hemodynamic, respiratory, and neurologic support as well as identification and treatment of reversible causes of cardiac arrest, temperature regulation, and control of metabolic abnormalities.77 Metabolic causes of cardiac arrest like hypovolemia, hypoxia, acidosis, hypokalemia, hyperkalemia, hypoglycemia, and hypothermia must be treated as soon as possible as they are reversible.77 Other treatable causes include tension pneumothorax, cardiac tamponade, pulmonary embolism, myocardial infarction, and toxins.77

**Hypothermia**

Moderate hypothermia after cardiac arrest due to ventricular fibrillation is a promising therapy that can be instituted in the intensive care unit. Two randomized, prospective clinical trials have shown improved survival and cerebral performance when therapeutic hypothermia was initiated in comatose out-of-hospital cardiac arrest patients after admission to the hospital.78, 79 The hypothermia after cardiac arrest study showed 41% mortality after the application of mild hypothermia (target temperature 32°C to 34°C) vs. 55% for standard of care, odds ratio for mortality: 0.74 (95% CI, 0.58-0.95; P = 0.02). The study also demonstrated a statistically significant favorable neurological outcome for the hypothermia group.78 Bernard et al also showed a 49% survival to discharge with good neurological outcomes vs. 26% for standard of care in out-of-hospital VT/VF cardiac arrest when cardiac arrest patients were cooled to a target temperature of 33°C for 12 hours (P = 0.046). The odds ratio for a good outcome in the hypothermia group compared to the normothermia group was 5.25 (95% CI, 1.47-18.76; P = 0.011).79 A protocol of therapeutic hypothermia with a target temperature of 33°C can successfully be implemented in intensive care units for comatose cardiac arrest patients with major benefit in patient outcome (**Class IIa**).77, 80

Core temperature should be monitored continuously and the patient can be externally cooled for 12 to 24 hours. Rewarming should be passive.80 Hypo-
thermic intervention may impact long-term survival as patients with severe neurological disability have poor long-term outcomes. Hypothermia may prevent neurological damage by decreasing the metabolic rate of neurons and by preventing reperfusion injury.\(^7\), \(^8\)

**Avoidance Of Hyperthermia**

Hyperthermia after successful resuscitation in cardiac arrest is associated with poor outcomes. In cardiac arrest patients in intensive care units, Zeiner et al demonstrated that the risk of poor neurological outcome increases 2.26 times (95% CI, 1.24-4.12) for each degree above 37°C. Thus, hyperthermia should be treated promptly during post-resuscitative care.\(^8\)

**Control of Blood Glucose Levels**

There is no specific evidence suggesting that glycemic control is as beneficial in cardiac arrest

---

**Clinical Pathway for Advanced Cardiovascular Life Support Pulseless Arrest**

**PULSELESS ARREST**

**Shockable rhythm?**

- **Shockable VT/VF**
  - Give one shock. Resume CPR (5 cycles) immediately. \(\text{(Class I)}\)
  - Check rhythm. Shockable rhythm?
    - **YES**
      - Give 1 shock. Resume CPR (5 cycles) immediately. \(\text{(Class Ila)}\)
        - Epinephrine IV/IO 1 mg every 3 to 5 minutes (Class Iib)
        - Vasopressin 40 IU IV/IO may replace first or second dose of epinephrine. \(\text{(Class Indeterminate)}\)
      - Check rhythm. Shockable rhythm?
        - **YES**
          - Give 1 shock. Resume CPR (5 cycles) immediately. Consider antiarrhythmics: Amiodarone \(\text{(Class Iib)}\) Lidocaine \(\text{(Class Indeterminate)}\) Magnesium \(\text{(Class Ila)}\)
        - **NO**
          - If pulse is present, begin post resuscitation care. If pulse is absent, treat as not shockable rhythm.

- **Not shockable Asystole/PEA**
  - Resume CPR (5 cycles) immediately. \(\text{(Class I)}\)
    - Epinephrine IV/IO 1 mg every 3 to 5 minutes. \(\text{(Class Iib)}\)
    - Vasopressin 40 IU IV/IO may replace first or second dose of epinephrine. \(\text{(Class Indeterminate)}\)
    - Atropine — 1 mg IV/IO for asystole or slow PEA rate. If needed, repeat every 3 to 5 minutes, up to 3 doses.
  - Check rhythm. Shockable rhythm?
    - **YES**
      - Treat as shockable rhythm.

See Table 2 on page 2 for class of evidence definitions.

This clinical pathway is intended to supplement, rather than substitute for, professional judgment and may be changed depending upon a patient's individual needs. Failure to comply with this pathway does not represent a breach of the standard of care.

Copyright © 2008 EB Practice, LLC. 1-800-249-5770. No part of this publication may be reproduced in any format without written consent of EB Practice, LLC.

Survival of the majority of cardiac arrest victims depends on the basic interventions of CPR and early delivery of electrical therapy rather than any of the currently applied or applicable advanced measures. Hypothermia is the only advanced intervention that has shown any survival benefit.

- **Don’t forget to activate the emergency response system.** Activation of the emergency response system both in-hospital and out-of-hospital will ensure timely arrival of trained personnel and a defibrillator. CPR should begin immediately after the activation of the emergency response system. Bystander CPR is an independent predictor of survival.
- **Make sure to check the carotid pulse for at least but no longer than 10 seconds.** This recommendation is not for lay people and is only for health care providers. Be careful not to take too long to check for carotid pulse. When pulse is not present, initiate chest compressions.
- **Make sure chest compressions are hard and fast.** Chest compression rates should be 100 per minute with avoidance of interruptions, which are common mistakes of health care providers.
- **Avoid rescuer fatigue.** Rescuers performing chest compressions should be frequently rotated. This will help to maintain continuous and fast chest compressions, which will ensure adequate cerebral and coronary perfusion pressures.
- **Allow chest wall to recoil completely.** Complete recoil increases negative intrathoracic pressure and facilitates venous return to the heart during CPR.
- **Attempt peripheral venous access prior to central access.** There is no evidence that central venous access is superior to peripheral venous access in terms of outcomes. Peripheral venous access should be attempted first as it does not interrupt CPR. If central access is attempted, make sure there is minimal interruption to CPR.
- **Do not hyperventilate the patient.** Even trained health care professionals can hyperventilate the patient during CPR. Hyperventilation may actually be harmful to the patient by impeding venous return to the heart because of high intrathoracic pressure.
- **Give 2 minutes of CPR prior to defibrillation if you suspect that the duration of cardiac arrest is longer than 4 to 5 minutes.** If the duration of cardiac arrest is greater than 4 minutes, the patient most likely is in the circulatory phase of cardiac arrest. At this time, circulatory support in the form of good quality CPR becomes as important as defibrillation. Hearts that are well perfused are more likely to respond to a defibrillatory shock.
- **Begin CPR immediately after each shock.** Cardiopulmonary resuscitation must resume immediately after each shock, as the heart is most likely in a non-perfusing rhythm in the first few seconds after defibrillation. Check the rhythm after 2 minutes of CPR; with identification of an organized rhythm, check the pulse. There is no evidence that chest compressions induce arrhythmias.
- **Use amiodarone as your first line antiarrhythmic drug.** Amiodarone is the only antiarrhythmic drug to show potential benefit in randomized clinical trials in the setting of shock refractory cardiac arrest. Lidocaine should not be used as a first-line agent.
Immediately resume CPR after each shock.

**Pathophysiology**

Negative intrathoracic pressures allow for better venous return to the heart.

**Remedy**

Ensure chest compressions at a rate of 100/minute.

Higher rates maintain Cerebral Perfusion Pressure (CPP) and coronary perfusion.

**Inadequate chest compression rates during CPR**

Allow for complete recoil.

Negative intrathoracic pressures allow for better venous return to the heart.

**Incomplete recoil of the chest wall during chest compressions**

Minimize interruptions to chest compressions; obtain peripheral access.

Interruptions to chest compressions result in low Cerebral Perfusion Pressure (CPP) and coronary perfusion.

**Prolonged interruptions to chest compressions for ventilation and central access placement**

**Hyperventilation of the cardiac arrest victims**

30:2 compression:ventilation ratio; give rescue breath for 1 second.

Higher intrathoracic pressures impede venous return to the heart.

**Failure to resume CPR after each shock**

Immediately resume CPR after each shock for 5 cycles only, then check the rhythm and pulse.

Heart may be in a non-perfusing rhythm immediately after defibrillation.

**Error**

Higher intrathoracic pressures impede venous return to the heart.

**Pathophysiology**

Immediate restoration of spontaneous circulation after CPR must be resumed immediately.

**Table 8: Common Errors in CPR Performance**

<table>
<thead>
<tr>
<th>Error</th>
<th>Remedy</th>
<th>Pathophysiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inadequate chest compression rates during CPR</td>
<td>Ensure chest compressions at a rate of 100/minute</td>
<td>Higher rates maintain Cerebral Perfusion Pressure (CPP) and coronary perfusion</td>
</tr>
<tr>
<td>Incomplete recoil of the chest wall during chest compressions</td>
<td>Allow for complete recoil</td>
<td>Negative intrathoracic pressures allow for better venous return to the heart</td>
</tr>
<tr>
<td>Prolonged interruptions to chest compressions for ventilation and central access placement</td>
<td>Minimize interruptions to chest compressions; obtain peripheral access</td>
<td>Interruptions to chest compressions result in low Cerebral Perfusion Pressure (CPP) and coronary perfusion</td>
</tr>
<tr>
<td>Hyperventilation of the cardiac arrest victims</td>
<td>30:2 compression:ventilation ratio; give rescue breath for 1 second</td>
<td>Higher intrathoracic pressures impede venous return to the heart</td>
</tr>
<tr>
<td>Failure to resume CPR after each shock</td>
<td>Immediately resume CPR after each shock for 5 cycles only, then check the rhythm and pulse</td>
<td>Heart may be in a non-perfusing rhythm immediately after defibrillation</td>
</tr>
</tbody>
</table>

**Therapeutic Hypothermia**

Even though there is strong evidence for induced hypothermia, it is not currently being widely implemented. Induced hypothermia has the potential to play a critical role in the post-resuscitative care of a small subset of cardiac arrest victims. Increased awareness about and induction of therapeutic hypothermia in select patients could translate into better outcomes with ACLS. Benefit of induced hypothermia was observed in a select subset of patients who were initially comatose but hemodynamically stable after a witnessed cardiac arrest with VF (Table 7). In the Hypothermia After Cardiac Arrest (HACA) study, only 8% of cardiac arrest victims were eligible to receive induced hypothermia. Similar therapy may be beneficial for patients with non-VF arrest in the out-of-hospital or in-hospital settings. Further experimental studies and clinical trials are required to determine optimal methods of cooling and optimal timing, duration, and intensity of cooling in order to achieve a measurable impact on CPR outcomes.

**Education Of Cardiovascular Patients And Their Families**

The majority of SCDs occur at home and are witnessed by relatives of cardiac arrest victims. In such cases, cardiac arrest victims do not receive adequate CPR from their relatives. See Table 8 for some of the most common CPR errors. Notably, 55% of SCD victims report cardiac symptoms 1 hour prior to collapse. The majority of SCD victims have a known history of either cardiovascular disease or cardiac symptoms. Educating relatives of patients with CVD in basic CPR may be an effective strategy to improve outcomes in out-of-hospital cardiac arrest.

**Summary**

Early initiation of CPR and defibrillation are the most effective measures with the highest impact on survival in patients suffering cardiac arrest. Increased public awareness is required, as witnessed arrests and bystander CPR are positive predictors of outcomes in out-of-hospital cardiac arrest. Cardiopulmonary resuscitation must be performed with a compression to ventilation ratio of 30:2, with minimal interruptions, and delivery of rescue breaths taking no more than 1 second. Basic BLS interventions take precedence over ACLS, as the latter is of limited efficacy. CPR must be resumed immediately after each shock for 5 cycles. Amiodarone is the only
antiarrhythmic with proven efficacy for the restoration of an organized rhythm in cardiac arrest. Benefit of lidocaine in restoring an organized rhythm is not yet established. Automated external defibrillators are simple, safe, and effective devices designed to be used by the general public, first responders, and hospital staff to convert VT/VF to perfusing rhythms in cardiac arrest patients. Educating cardiovascular patients and their families to recognize symptoms preceding SCD, in order to call for help when symptoms are present and to provide CPR when collapse occurs, are important steps to improve outcomes. High quality post-resuscitative care is an important component of management of cardiac arrest with emphasis on treatment of reversible causes and metabolic conditions. Therapeutic hypothermia is effective in a select subset of cardiac arrest patients.

Case Conclusion

Cardiopulmonary resuscitation was immediately initiated. As the downtime was not known, the patient received 2 minutes of CPR, with a chest compression and ventilation ratio of 30:2. While CPR was ongoing, a biphasic AED was attached, which showed coarse VF. Peripheral venous access was established without interruption of CPR. After 2 minutes of CPR (approximately 5 cycles of compression and ventilation), the patient received his first shock. A pulse was detected after 2 minutes of CPR after the first shock, and the AED showed sinus rhythm. The patient regained consciousness with establishment of spontaneous circulation. The patient’s ECG immediately after resuscitation showed ST-segment elevation in V1 to V3 with reciprocal changes in inferior leads, consistent with anterior myocardial injury. He was immediately taken to the cardiac catheterization laboratory and received percutaneous coronary intervention to the left anterior descending epicardial coronary artery. Subsequent blood chemistry revealed elevated cardiac enzymes. Since he was not comatose, he was not deemed to be a candidate for induced hypothermia. His blood glucose was closely monitored and kept between 80 and 110 mg/dL by an insulin infusion. He had 1 episode of elevated temperature of 38°C after the procedure, which was promptly treated. The patient’s electrolytes were closely monitored and any deficiency was corrected. He was discharged home neurologically intact.

References

Evidence-based medicine requires a critical appraisal of the literature based upon study methodology and number of subjects. Not all references are equally robust. The findings of a large, prospective, randomized, and blinded trial should carry more weight than a case report.

23. Kern KB, Hilwig RW, Berg RA, Sanders AB, Ewy GA. Importance


42. Weaver WD, Cobb LA, Hallstrom AP. Ventricular defibrillation-


68. Brown DC, Lewis AJ, Criley JM. Asystole and its treatment: the possible role of the parasympathetic nervous system in cardiac arrest. JACEP 1979;8:448-52. (Prospective, 8 patients)


75. Weaver WD, Fahrenbruch CE, Johnson DD, Hallstrom AP, Cobb LA, Copass MK. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation. Circulation. 1990;82:2027-34. (RCT, 199 patients)


CME Questions

1. What is the correct chest compression to ventilation ration in adult CPR?
   a. 15:2
   b. 10:2
   c. 30:2
   d. 30:4

2. What is the incidence of VT/VF cardiac arrest in adults?
   a. 50% to 60%
   b. 21% to 32%
   c. 10% to 16%
   d. 72% to 82%

3. What are the 2 most common underlying etiologies of SCD?
   a. CAD and cardiomyopathies
   b. CAD and WPW syndrome
   c. Cardiomyopathies and WPW syndrome
   d. Drug effects and WPW syndrome

4. Which of the following statements is false?
   a. Biphasic devices have higher first shock success rates than monophasic devices.
   b. Repeated shocks with monophasic devices may produce atrioventricular block.
   c. Biphasic devices use lower energy levels than monophasic devices.
   d. Biphasic devices have shown a survival benefit when compared to monophasic devices.
5. Which CPR intervention has the largest impact on survival in cardiac arrest?
   a. Good quality CPR and early defibrillation
   b. Frequent ventilation of the patient
   c. Intubation and placement of a central venous access
   d. Use of antiarrhythmics
   e. Controlled hypothermia

6. Immediately after the delivery of a first shock you should:
   a. Check the rhythm on the monitor.
   b. Palpate the carotid pulse.
   c. Begin CPR for 2 minutes.
   d. Check the patient’s blood pressure.

7. Regarding the use of vasopressors in cardiac arrest, which of the following is true?
   a. Use of higher doses of epinephrine results in a higher rate of survival to discharge.
   b. Vasopressin is superior to epinephrine in all forms of cardiac arrest.
   c. Epinephrine is effective in an acidic environment where vasopressin is not.
   d. Vasopressin 40 IU can replace the first or second dose of epinephrine during ACLS.

8. The use of which antiarrhythmic in cardiac arrest has been shown in clinical trials to improve survival to hospital admission?
   a. Amiodarone
   b. Procainamide
   c. Lidocaine
   d. Ibutilide

9. Which of the post-resuscitative measures have shown to improve outcomes in cardiac arrest patients?
   a. Hyperthermia
   b. Hypothermia
   c. Hyperglycemia
   d. Hypoglycemia

10. Use of amiodarone in cardiac arrest results in higher incidence of hypotension when compared to lidocaine
    a. True
    b. False

Physician CME Information


Accreditation: This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of EB Medicine. EB Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: EB Medicine designates this educational activity for a maximum of 48 AMA PRA Category 1 Credit(s)™ per year. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ACEP Accreditation: Emergency Medicine Practice is approved by the American College of Emergency Physicians for 48 hours of ACEP Category 1 credit per annual subscription.

AAFP Accreditation: Emergency Medicine Practice has been reviewed and is acceptable for up to 48 Prescribed credits per year by the American Academy of Family Physicians. AAFP Accreditation begins August 1, 2006. Term of approval is for two years from this date. Each issue is approved for 4 Prescribed credits. Credits may be claimed for two years from the date of this issue.

AOA Accreditation: Emergency Medicine Practice has been approved for 48 Category 2B credit hours per year by the American Osteopathic Association.

Needs Assessment: The need for this educational activity was determined by a survey of medical staff, including the editorial board of this publication; review of morbidity and mortality data from the CDC, NCHS, and AHA, and evaluation of prior activities for emergency physicians.

Target Audience: This enduring material is designed for emergency medicine physicians, physician assistants, nurse practitioners, and residents.

Goals & Objectives: Upon completion of this article, you should be able to:
   1. Demonstrate medical decision-making based on the strongest clinical evidence.
   2. Cost-effectively diagnose and treat the most critical ED presentations.
   3. Describe the most common medicolegal pitfalls for each covered topic.

Discussion of Investigational Information: As part of the newsletter, faculty may be presenting investigational information about pharmaceutical products that is outside Food and Drug Administration-approved labeling. Information presented as part of this activity is intended solely as continuing medical education and is not intended to promote off-label use of any pharmaceutical product.

Disclosure of Off-Label Usage: This issue of Emergency Medicine Practice discusses no off-label use of any pharmaceutical product.

Faculty Disclosure: It is the policy of EB Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices.

In compliance with all ACCME Essentials, Standards, and Guidelines, all faculty for this CME activity were asked to complete a full disclosure statement. The information received is as follows: Dr. Ali, Dr. Zafari, Dr. Bobrow and Dr. Richardson report no significant financial interest in the products or topics discussed in this educational presentation.

Hardware/Software Requirements: You will need a Macintosh or PC to access the online archived articles and CME testing. Adobe Reader is required to view the PDFs of the archived articles. Adobe Reader is available as a free download at www.adobe.com.

Opinions expressed are not necessarily those of this publication. Mention of products or services does not constitute endorsement. This publication is intended as a general guide and is intended to supplement, rather than substitute, professional judgment. It covers a highly technical and complex subject and should not be used for making specific medical decisions.

The materials contained herein are not intended to establish policy, procedure, or standard of care. Emergency Medicine Practice is a trademark of EB Practice, LLC. Copyright © 2008 EB Practice, LLC. All rights reserved. No part of this publication may be reproduced in any format without written consent of EB Practice, LLC. This publication is intended for the use of the individual subscriber only and may not be copied in whole or in part or redistributed in any way without the publisher’s prior written permission—including reproduction for educational purposes or for internal distribution within a hospital, library, group practice, or other entity.